HalozymeHALO
HALO
About: Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Employees: 373
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
94% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 47
82% more call options, than puts
Call options by funds: $23.1M | Put options by funds: $12.7M
10% more capital invested
Capital invested by funds: $6.47B [Q2] → $7.1B (+$632M) [Q3]
10% more funds holding
Funds holding: 456 [Q2] → 500 (+44) [Q3]
7% more repeat investments, than reductions
Existing positions increased: 177 | Existing positions reduced: 166
0.95% more ownership
Funds ownership: 97.03% [Q2] → 97.98% (+0.95%) [Q3]
55% less funds holding in top 10
Funds holding in top 10: 11 [Q2] → 5 (-6) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$52
11%
upside
Avg. target
$64
36%
upside
High target
$73
55%
upside
4 analyst ratings
2 positive
50%
2 neutral
50%
0 negative
0%
HC Wainwright & Co. Mitchell Kapoor 25% 1-year accuracy 41 / 165 met price target | 45%upside $68 | Buy Reiterated | 18 Dec 2024 |
Piper Sandler Joseph Catanzaro 32% 1-year accuracy 10 / 31 met price target | 11%upside $52 | Neutral Maintained | 4 Nov 2024 |
JMP Securities Jason Butler 33% 1-year accuracy 13 / 40 met price target | 55%upside $73 | Market Outperform Maintained | 1 Nov 2024 |
Wells Fargo Mohit Bansal 28% 1-year accuracy 7 / 25 met price target | 32%upside $62 | Equal-Weight Downgraded | 7 Oct 2024 |
Financial journalist opinion
Based on 14 articles about HALO published over the past 30 days
Positive
Zacks Investment Research
5 days ago
How Much Upside is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08%
The average of price targets set by Wall Street analysts indicates a potential upside of 27.1% in Halozyme Therapeutics (HALO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
1 week ago
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Positive
Zacks Investment Research
1 week ago
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Positive
Zacks Investment Research
1 week ago
Is Halozyme Therapeutics (HALO) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Positive
Zacks Investment Research
2 weeks ago
Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now
Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.
Positive
Zacks Investment Research
2 weeks ago
HALO vs. FOLD: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two stocks is more attractive to value investors?
Positive
Zacks Investment Research
2 weeks ago
Is Halozyme Therapeutics (HALO) Outperforming Other Medical Stocks This Year?
Here is how Halozyme Therapeutics (HALO) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
Neutral
PRNewsWire
3 weeks ago
Halozyme to Present at Upcoming Investor Conferences
SAN DIEGO , Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the executive leadership team are scheduled to present and host investor meetings at the following investor conferences. Details on the presentations are as follows: Event: Piper Sandler 36th Annual Healthcare Conference Presenter: Nicole LaBrosse, Chief Financial Officer Format: Fireside Chat and 1x1 Meetings Presentation Date: Wednesday, December 4, 2024 Presentation Time: 10:30am PT / 1:30pm ET Location: New York, NY Event: 7th Annual Evercore ISI HealthCONx Conference Presenter: Helen Torley, President and Chief Executive Officer Format: Fireside Chat and 1x1 Meetings Presentation Date: Wednesday, December 4, 2024 Presentation Time: 9:30am PT / 12:30pm ET Location: Miami, FL A live audio webcast of the presentations will be available in the Investor Relations section of the Company's website.
Neutral
Zacks Investment Research
3 weeks ago
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up
Halozyme withdraws its proposal to acquire Evotec for 11 euro per share in cash. The company maintains its 2024 revenue guidance.
Positive
Zacks Investment Research
4 weeks ago
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why
Halozyme Therapeutics (HALO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Charts implemented using Lightweight Charts™